Author: Emma Yasinski

Emma Yasinski

I am a freelance science and medical journalist, fascinated by how the scientific process leads to incredible discoveries, but also can lead to publication bias leaning toward positive findings and minimizing negatives. With a bachelor’s degree in neuroscience from Lafayette College and a Master’s in Science and Medical Journalism from Boston University, I’ve written about clinical trial transparency, organ donation, and basic molecular biology for publications like The Scientist, The Atlantic, Undark.org, Kaiser Health News, and more. At MedShadow, I research and write about the sometimes unexpected ways that medicines can affect us, and what we can do if and when it does.

The Mpox (formerly known as monkeypox) outbreak in the US hit its peak in August of 2022, and has declined from causes about 400 illnesses a day to just one, but that doesn’t mean the danger is completely gone, the Centers for Disease Control and Prevention explained in a teleconference on May 18, 2023. In May 2023, the World Health Organization (WHO) declared an end to the global health emergency. While cases are fewer, breakouts are still happening. Between mid April 2023 and early May, experts identified an outbreak of 21 men with Mpox in the Chicago area. “All have…

Read More

​Early in Dee Mangin’s career as a primary-care physician, she noticed that many people, especially older adults, were prescribed large numbers and doses of drugs, which, in some cases, might actually be detracting from their health rather than improving it. Then, she realized that even when polypharmacy (being prescribed five or more medications simultaneously) was recognized as a problem, there wasn’t any systematic way to help patients and healthcare providers assess which medicines might be most effective in a lower dose or discontinued altogether.  Mangin is an MBChB (the New Zealand equivalent of an MD) and DPH (doctor of public…

Read More

Shingles is not your average rash. The painful, itchy red stripe caused by shingles can last up to 10 days, while long-term nerve pain, a common complication, can persist for months or years. In the rare event that the outbreak appears on your face, it can even cause blindness. Luckily, there’s a two-dose vaccine, Shingrix (zoster vaccine recombinant, adjuvanted), that can prevent the disease. It’s recommended for people 50 years and older, even if you’ve already had shingles, and those 19 and older who are immunosuppressed. Shingles is a unique disease in that it’s not caused by a new infection.…

Read More